In the realm of geriatric care, where the lines between natural aging and neurodegenerative diseases can be blurred, a recent study has shed light on the profound impact of Alzheimer's disease biomarkers in very old adults. This research, led by the Sant Pau Research Institute (IR Sant Pau), challenges the long-held belief that cognitive decline in the elderly is an inevitable and unpreventable part of the aging process. Instead, it reveals the power of early detection and the potential for personalized medicine in this vulnerable population.
The Unseen Impact of Cognitive Decline
For decades, cognitive decline in very old adults has been largely dismissed as a natural consequence of aging. This perspective has led to a culture of acceptance where memory problems in patients over 80 are often attributed to the aging process without further investigation. However, as the study by Dr. Chiara Ceriello and her team at IR Sant Pau demonstrates, this approach is both inaccurate and potentially harmful.
One of the key challenges in addressing cognitive decline in the very old is the reliance on clinical assessments alone. These assessments, while valuable, can be limited in their ability to discern between the effects of aging and the early stages of neurodegenerative diseases like Alzheimer's. The presence of multiple coexisting conditions at advanced ages further complicates this, making it difficult to pinpoint the exact cause of cognitive decline.
Dr. Ceriello highlights the issue: "Without biomarkers, clinical diagnosis is particularly inaccurate at advanced ages. Many patients over 80 are evaluated without the use of biomarkers, introducing a high degree of uncertainty regarding the true cause of their symptoms. This approach, which remains widespread among clinicians, is largely justified by the high frequency of coexisting conditions at advanced ages."
The Power of Alzheimer's Disease Biomarkers
The study, published in Neurology, analyzed 167 individuals over 80 with mild cognitive impairment from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort. The results were striking: nearly 70% of these individuals had biology consistent with Alzheimer's disease, as determined by the analysis of characteristic proteins in cerebrospinal fluid and blood. This finding challenges the notion that biomarkers have limited value at very advanced ages.
Dr. Ignacio Illán-Gala, a researcher with the Neurobiology of Dementias Group at IR Sant Pau and one of the study's authors, explains: "Not every memory problem after age 80 is normal. Assuming that it is can lead to the underdiagnosis of diseases such as Alzheimer's. We need to overcome the influence of ageism in the care of these patients and move toward a more accurate diagnosis, including at advanced ages."
The study found that patients with Alzheimer's disease biology experienced more rapid cognitive decline than those without evidence of the disease. This difference, though seemingly small on an annual basis, becomes clinically significant when considered cumulatively. It translates into more rapid progression toward greater impairment and loss of independence. Similarly, the presence of these biomarkers was associated with a higher risk of progressing to dementia during follow-up.
The Practical Implications
One of the most exciting aspects of this study is the potential for translating these findings into clinical practice. The use of blood-based biomarkers, such as p-Tau217, offers a simpler and more broadly applicable approach to diagnosis. This is particularly relevant in geriatric care, where the systematic use of more complex procedures has historically been limited.
Dr. Ceriello emphasizes the practical implications: "The availability of a blood-based biomarker makes it much easier to incorporate this assessment into clinical practice, particularly for older patients. It allows us to obtain relevant biological information in a simpler and more practical way, and this has a direct impact on how we assess and monitor these patients."
The study challenges the practice of excluding people over 80 from biomarker-based diagnostic strategies. It points to the need for a more individualized approach, where chronological age alone does not reflect the heterogeneity of this population. For patients with good functional status and long life expectancy, a more accurate diagnosis may have a significant impact on clinical management, prognosis, and future planning.
The Future of Alzheimer's Disease Care
The arrival of new drugs capable of modifying the course of Alzheimer's disease further underscores the importance of early and accurate diagnosis. These treatments have demonstrated the ability to slow the progression of cognitive decline, making it even more crucial to identify patients who could benefit from them.
Dr. Illán-Gala reflects on the broader implications: "We are seeing increasing numbers of older people seeking care because they have noticed changes in their memory and want to know what is happening to them and what they can expect. Answering these questions is part of providing appropriate care."
In conclusion, this study demonstrates that Alzheimer's disease biomarkers retain significant clinical value in people aged 80 and older. Their use can help improve diagnosis and decision-making in a growing population that has so far been underrepresented in research. As we continue to navigate the complexities of cognitive decline in the very old, the insights from this study offer a beacon of hope for more accurate, personalized, and effective care.
